CLINICAL TRIALS PROFILE FOR TRIJARDY XR
✉ Email this page to a colleague
All Clinical Trials for TRIJARDY XR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT07213895 ↗ | Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy XR Extended Release Film Coated Tablets | COMPLETED | Humanis Saglk Anonim Sirketi | PHASE1 | 2025-05-21 | Randomized, Single Oral Dose, Two-period, Two Sequence, Open-label, Crossover, Bioequivalence Study to Compare Empagliflozin-Linagliptin-Metformin XR Tablet 25mg/ 5mg/1000mg (25mg Empagliflozin /5mg Linagliptin /1000mgMetformin Hydrochloride) Versus Trijardy XR Tablets (25mg Empagliflozin /5mg Linagliptin /1000mg Metformin Hydrochloride), in Healthy Subjects Under Fed Conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRIJARDY XR
Condition Name
Clinical Trial Locations for TRIJARDY XR
Clinical Trial Progress for TRIJARDY XR
Clinical Trial Phase
Clinical Trial Sponsors for TRIJARDY XR
Sponsor Name
